ATyr Pharma: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
== ATyr Pharma == | |||
[[File:ATyr_Pharma_logo.svg|thumb|right|Logo of ATyr Pharma]] | |||
'''ATyr Pharma''' is a biotechnology company focused on the discovery and development of innovative medicines based on novel biological pathways. The company is headquartered in [[San Diego, California]], and it specializes in the research of [[tRNA synthetase]] biology and its applications in treating various diseases. | |||
ATyr Pharma | |||
== | === History === | ||
ATyr Pharma was founded in 2005 by Dr. Paul Schimmel, a renowned scientist in the field of tRNA synthetase biology. The company was established to explore the therapeutic potential of proteins derived from tRNA synthetases, which are enzymes that play a crucial role in the translation of genetic information into proteins. | |||
=== | === Research and Development === | ||
ATyr Pharma's research | ATyr Pharma's research focuses on a class of proteins known as [[Physiocrines]], which are derived from tRNA synthetases. These proteins have been found to have diverse biological functions, including roles in [[immune modulation]], [[tissue regeneration]], and [[inflammation]]. The company is investigating these proteins as potential treatments for a variety of diseases, including [[pulmonary disease]], [[cancer]], and [[autoimmune disorders]]. | ||
== | === Pipeline === | ||
The company's lead therapeutic candidate is ATYR1923, a fusion protein that targets the neuropilin-2 (NRP2) receptor. ATYR1923 is being developed for the treatment of interstitial lung diseases, including [[pulmonary sarcoidosis]] and other forms of [[fibrosis]]. | |||
==Collaborations | === Collaborations === | ||
ATyr Pharma has established collaborations with | ATyr Pharma has established collaborations with several academic institutions and research organizations to advance its scientific discoveries. These partnerships aim to enhance the understanding of tRNA synthetase biology and accelerate the development of new therapeutic approaches. | ||
==Corporate Structure== | === Corporate Structure === | ||
The company is led by a team of experienced executives and scientists with expertise in biotechnology and drug development. ATyr Pharma is publicly traded on the [[NASDAQ]] stock exchange under the ticker symbol "LIFE." | The company is led by a team of experienced executives and scientists with expertise in biotechnology and drug development. ATyr Pharma is publicly traded on the [[NASDAQ]] stock exchange under the ticker symbol "LIFE." | ||
==Related pages== | == Related pages == | ||
* [[Biotechnology]] | * [[Biotechnology]] | ||
* [[tRNA synthetase]] | |||
* [[Drug development]] | * [[Drug development]] | ||
* [[ | * [[Pulmonary disease]] | ||
[[Category:Biotechnology companies]] | |||
[[Category:Companies based in San Diego, California]] | |||
[[Category:Pharmaceutical companies of the United States]] | |||
[[Category:Biotechnology companies | |||
[[Category:Companies based in San Diego]] | |||
[[Category:Pharmaceutical companies | |||
Latest revision as of 11:04, 15 February 2025
ATyr Pharma[edit]
ATyr Pharma is a biotechnology company focused on the discovery and development of innovative medicines based on novel biological pathways. The company is headquartered in San Diego, California, and it specializes in the research of tRNA synthetase biology and its applications in treating various diseases.
History[edit]
ATyr Pharma was founded in 2005 by Dr. Paul Schimmel, a renowned scientist in the field of tRNA synthetase biology. The company was established to explore the therapeutic potential of proteins derived from tRNA synthetases, which are enzymes that play a crucial role in the translation of genetic information into proteins.
Research and Development[edit]
ATyr Pharma's research focuses on a class of proteins known as Physiocrines, which are derived from tRNA synthetases. These proteins have been found to have diverse biological functions, including roles in immune modulation, tissue regeneration, and inflammation. The company is investigating these proteins as potential treatments for a variety of diseases, including pulmonary disease, cancer, and autoimmune disorders.
Pipeline[edit]
The company's lead therapeutic candidate is ATYR1923, a fusion protein that targets the neuropilin-2 (NRP2) receptor. ATYR1923 is being developed for the treatment of interstitial lung diseases, including pulmonary sarcoidosis and other forms of fibrosis.
Collaborations[edit]
ATyr Pharma has established collaborations with several academic institutions and research organizations to advance its scientific discoveries. These partnerships aim to enhance the understanding of tRNA synthetase biology and accelerate the development of new therapeutic approaches.
Corporate Structure[edit]
The company is led by a team of experienced executives and scientists with expertise in biotechnology and drug development. ATyr Pharma is publicly traded on the NASDAQ stock exchange under the ticker symbol "LIFE."
